BioSyent Inc. (V:RX*CA)
Business Focus: Pharmaceuticals (NEC)
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 2476 Argentia Road, Suite 402 MISSISSAUGA ON L5N 6M1 |
| Tel: | N/A |
| Website: | https://www.biosyent.com |
| IR: | See website |
| Key People | ||
| Rene C. Goehrum Chairman of the Board, President, Chief Executive Officer | Robert Joseph March Chief Financial Officer, Vice President - Finance | Joost Van Der Mark Vice President- Corporate Development |
| Kevin Wilson Vice President - Community Health Business | Neelu Atwal Director - Human Resources | Ramesh Moothan Director - International Business Unit | Sharan Raghubir Director - Specialty Business Unit |
| Business Overview |
| BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company's business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Biosyent Inc revenues increased 13% to C$31.6M. Net income increased 18% to C$6.5M. Revenues reflect Pharmaceutical Business segment increase of 14% to C$30.6M. Net income benefited from Finance income increase from C$526K to C$1.1M (income), Research and Development decrease of 31% to C$83K (expense). Dividend per share increased from C$0.04 to C$0.16. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $75.43M as of Dec 31, 2023 |
| Annual revenue (TTM): | $31.59M as of Dec 31, 2023 |
| EBITDA (TTM): | $7.99M as of Dec 31, 2023 |
| Net annual income (TTM): | $6.46M as of Dec 31, 2023 |
| Free cash flow (TTM): | $3.08M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 11,797,209 as of Apr 2, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.